Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp > insider buys
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1962)
•••
Post by Possibleidiot01on Dec 22, 2023 3:14pm
231 Views
Post# 35798309

insider buys

insider buys
  • Profound Medical Corp. (TSE:PRN - Get Free Report) Senior Officer Rashed Osman Dewan acquired 9,747 shares of the business's stock in a transaction that occurred on Tuesday, August 15th. The shares were bought at an average price of C$12.95 per share, for a total transaction of C$126,223.65.
 
  • Profound Medical Corp. (TSE:PRN - Get Free Report) Director Arun Menawat Dr. acquired 24,558 shares of the business's stock in a transaction dated Tuesday, August 15th. The stock was purchased at an average price of C$12.95 per share, with a total value of C$318,026.10.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities